|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||246.354 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
5-MeO-MiPT is a psychedelic and hallucinogenic drug, used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a "substitute" for 5-MeO-DiPT because of the very similar structure and effects.
5-MeO-MiPT is in a class of compounds commonly known as tryptamines, and is the N-methyl-N-isopropyl homologue of the psychedelic, 5-MeO-DMT. The full name of the chemical is 5-methoxy-N-methyl-N-isopropyltryptamine.
This is an analogue of the more popular drug 5-MeO-DiPT (nicknamed "foxy methoxy") and has the nickname "moxy". Some users report the tactile effects of 5-MeO-DiPT without some of the unwanted side effects. At higher doses it becomes much more psychedelic sometimes being compared to 5-MeO-DMT. But at doses of 4-10 milligrams users find 5-MeO-MiPT to be a very euphoric and tactile chemical. Its energetic effects can be very strong at high doses, increasing normal heart rate considerably. Sounds can be amplified in perception to a point where synesthetic effects ("touching or/and tasting sounds") occur.
|Binding Sites||Binding Affinity Ki (μM)|
|Threshold||5 mg||3 mg|
|Light||5 - 10 mg||3 - 7 mg|
|Common||10 - 15 mg||7 - 15 mg|
|Strong||15 - 20 mg||15 - 20 mg|
|Heavy||20 mg +||20 mg +|
The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-MiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as inhibition of MAO may be involved also. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, it also shows fairly strong binding affinity to the SERT and NET, thereby acting as a moderately potent serotonin-norepinephrine reuptake inhibitor. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from protestkit.
|Freebase||Orange to brown||Orange red||Deep greenish brown||Unknown||Purple||No reaction||No reaction|
|HCl||Orange to brown||Red to brown||Greenish brown||Brown||Violet to purple||Green||Unknown|
The toxicity of 5-MeO-MiPT is not known. There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.
As of October 2015 5-MeO-MiPT is a controlled substance in China.
5-MeO-MiPT is unscheduled at the federal level in the United States, but it could be considered an analog of 5-MeO-DiPT, in which case purchase, sale, or possession with intent to consume could be prosecuted under the Federal Analog Act.
- Spratley, Trinette (2004). "Analytical Profiles for Five "Designer" Tryptamines" (PDF). Microgram Journal. 3 (1–2): 55. Retrieved 2013-10-09.
- Carpenter, David E. (2022-01-25). "DEA Proposes Adding Five Psychedelic Compounds to Schedule 1". Lucid News. Retrieved 2022-01-26.
- Rickli A.; Moning O.D.; Hoener M.C.; Liechti M.E. (2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens" (PDF). European Neuropsychopharmacology. 26 (8): 1327–37. doi:10.1016/j.euroneuro.2016.05.001. PMID 27216487. S2CID 6685927.
- "Erowid Online Books : "TIHKAL" - #40 5-MEO-MIPT". www.erowid.org. Retrieved 2021-06-01.
- "5-MeO-MIPT (also 5-Methoxy-N,N-Methylisopropyltryptamine) : Erowid Exp: Main Index". www.erowid.org. Retrieved 2021-06-01.
- Repke DB, Grotjahn DB, Shulgin AT (July 1985). "Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents". Journal of Medicinal Chemistry. 28 (7): 892–6. doi:10.1021/jm00145a007. PMID 4009612.
- Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–7. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
- Ray, T. S. (2010). "Psychedelics and the Human Receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
- Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie.
- "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.
- Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL